Categories: All postsAnalysts

Take a pass on Celestica, Beacon Securities says

A year of rebuilding lies ahead for Celestica (Celestica Stock Quote, Chart TSX, NYSE:CLS), according to Gabriel Leung, analyst for Beacon Securities, who in an update to clients on Thursday reacted to the company’s quarterly results by dropping his rating from “Buy” to “Hold” while trimming his price target from $10.50 to $9.00.

Electronic Manufacturing Services company Celestica released its first quarter fiscal 2019 financials on Wednesday, coming in with revenues of $1.43 billion and earnings per share of $0.12 per share. Management had guided for between $1.45 and $1.55 billion and between $0.12 and $0.18 per share, respectively. (All figures in US dollars.)

The results were below Leung’s forecast of $1.48 billion and $0.17 per share, respectively. The analyst noted that revenues within the company’s Advanced Technology Solutions segment, representing 40 per cent of revenues, were impacted by demand weakness in semiconductor capital equipment, costs associated with the ramping of multiple new programs within industrial and health tech and materials shortages within aerospace and defense.

Leung notes that CLS has guided for Q2 revenues and EPS to be between $1.4 and $1.5 billion and between $0.09 and $0.15 per share, respectively, which is lower than the consensus expectation of $1.6 billion and $0.22 per share.

“Clearly, 2019 is turning into a year of rebuilding for CLS as it optimizes its operations to the realities of a slower demand environment. That said, we believe there could be upside via market share gains and as the demand picture improves given the potential operating leverage within the company’s business model,” says Leung.

Leung’s $9.00 target is derived from a 13x 2019 P/E estimate and amounts to a projected return of 17 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: cls
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

23 hours ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

24 hours ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

1 day ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

2 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

2 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

2 days ago